Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2024-07-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
监事会关于公司向特定对象发行A股股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's issuance of A-shares to specific investors. It discusses compliance with laws and regulations, the issuance plan, use of funds, shareholder approvals, and related party transactions. It is a formal opinion or review related to a capital raising event but does not contain financial statements or detailed financial data. The document length is 2237 characters, which is relatively short and more consistent with an announcement or opinion rather than a full report. The content focuses on the issuance of shares to specific parties, which aligns with capital/financing activities. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2024-07-29 Chinese
关于公司2024年度向特定对象发行A股股票摊薄即期回报的风险提示及填补措施与相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the risk of immediate return dilution due to a specific issuance of A shares by Shenzhen Haiwang Bioengineering Co., Ltd. It includes financial impact analysis, assumptions, risk warnings, necessity and rationality of the issuance, use of raised funds, measures to mitigate dilution risk, and commitments from controlling shareholders and management. The content focuses on capital raising activities, specifically a targeted share issuance, and its financial implications. There is no full financial report or earnings data presented, but rather a detailed update on a capital/financing event and related risk disclosures. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2024-07-29 Chinese
2024年度向特定对象发行A股股票方案的论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "2024年度向特定对象发行股票方案的论证分析报告" from Shenzhen Haiwang Bioengineering Co., Ltd. It discusses the company's plan to issue shares to specific investors, including the background, purpose, legal compliance, pricing, and impact analysis of the share issuance. The content includes detailed financial data, regulatory references, and strategic rationale for the capital raising. This is a comprehensive analysis report related to a capital raising activity (private placement of shares). It is not a simple announcement or a brief summary but a full analytical report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-07-29 Chinese
关于无需编制前次募集资金使用情况的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company regarding the non-requirement to prepare a report on the use of previously raised funds. It references regulatory guidelines and states that no new report or audit is needed because the previous funds have been fully used and the time period exceeds five years. The document does not contain financial statements or detailed financial data, nor is it a full report. It is an official announcement about the status of a report requirement, fitting the category of Regulatory Filings (RNS) as it is a compliance-related disclosure without substantive financial data or a full report attached.
2024-07-29 Chinese
关于控股股东、实际控制人拟发生变更的提示性公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding a proposed change in the controlling shareholder and actual controller of Shenzhen Neptunus Bioengineering Co., Ltd. It includes specifics about share transfer agreements, voting rights waiver agreements, shareholding percentages before and after the transaction, payment terms, governance changes including board and supervisory appointments, performance commitments, and other related contractual obligations. The content focuses on ownership changes, control transfer, and related agreements rather than financial results, audit opinions, or earnings. It is not a full annual or interim report, nor an earnings release or call transcript. It is also not a proxy solicitation or voting results announcement. The document is a formal disclosure of a significant change in the company's board control and ownership structure, which fits the category of Board/Management Information (MANG). The length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is MANG with high confidence.
2024-07-29 Chinese
关于提供财务资助的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of financial assistance provided to its subsidiaries. It details board meetings and shareholder meetings where financial assistance matters were approved, the amounts involved, repayments received, risk analysis, and control measures. The document is relatively short (1548 characters) and focuses on updates about financing activities rather than presenting financial statements or comprehensive financial data. It does not contain full financial reports or detailed financial analysis but rather updates on financing-related matters. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-06-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.